

# "Schizotaxia": Clinical Implications and New Directions

Schizophrenia Bulletin

27, 1-18

DOI: [10.1093/oxfordjournals.schbul.a006849](https://doi.org/10.1093/oxfordjournals.schbul.a006849)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Toward Reformulating the Diagnosis of Schizophrenia. American Journal of Psychiatry, 2000, 157, 1041-1050.	7.2	174
2	Towards the prevention of schizophrenia. Biological Psychiatry, 2000, 48, 349-356.	1.3	61
3	Concurrent validation of schizotaxia: a pilot study. Biological Psychiatry, 2001, 50, 434-440.	1.3	35
4	Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biological Psychiatry, 2001, 50, 873-883.	1.3	339
5	Prodromes of first-episode psychosis: How can we challenge nonspecificity?. Comprehensive Psychiatry, 2001, 42, 382-392.	3.1	21
6	Genes, environment and schizophrenia. British Journal of Psychiatry, 2001, 178, s18-s24.	2.8	230
7	Left Hippocampal Volume as a Vulnerability Indicator for Schizophrenia. Archives of General Psychiatry, 2002, 59, 839.	12.3	237
8	Understanding Predisposition to Schizophrenia: Toward Intervention and Prevention. Canadian Journal of Psychiatry, 2002, 47, 518-526.	1.9	42
9	Endophenotyping schizotypy: a prelude to genetic studies within the schizophrenia spectrum. Schizophrenia Research, 2002, 54, 47-57.	2.0	55
10	An integration of schizophrenia with schizotypy: identification of schizotaxia and implications for research on treatment and prevention. Schizophrenia Research, 2002, 54, 169-175.	2.0	91
11	Neurological soft-signs in psychosis: threshold criteria for discriminating normal controls and for predicting cognitive impairment. Schizophrenia Research, 2002, 58, 263-271.	2.0	38
12	Molecular genetic studies of schizophrenia: challenges and insights. Neuroscience Research, 2002, 43, 295-304.	1.9	50
13	Preventing Schizophrenia and Psychotic Behaviour: Definitions and Methodological Issues. Canadian Journal of Psychiatry, 2002, 47, 527-537.	1.9	19
14	Diagnostic Concepts and the Prevention of Schizophrenia. Canadian Journal of Psychiatry, 2002, 47, 515-517.	1.9	6
15	Treatment of nonpsychotic relatives of patients with schizophrenia: Six case studies. American Journal of Medical Genetics Part A, 2002, 114, 943-948.	2.4	17
16	Schizotaxia: Current status and future directions. Current Psychiatry Reports, 2003, 5, 128-134.	4.5	20
17	Genetically mediated brain abnormalities in schizophrenia. Current Psychiatry Reports, 2003, 5, 135-144.	4.5	25
18	Boundaries of schizophrenia. Psychiatric Clinics of North America, 2003, 26, 1-23.	1.3	34

#	ARTICLE	IF	CITATIONS
19	Sensitivity and Specificity of Memory Dysfunction in Schizophrenia: A Comparison With Major Depression. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2003, 25, 79-93.	1.3	96
20	Psychosis as a State of Aberrant Salience: A Framework Linking Biology, Phenomenology, and Pharmacology in Schizophrenia. <i>American Journal of Psychiatry</i> , 2003, 160, 13-23.	7.2	2,311
21	A Review and New Report of Medial Temporal Lobe Dysfunction as a Vulnerability Indicator for Schizophrenia: A Magnetic Resonance Imaging Morphometric Family Study of the Parahippocampal Gyrus. <i>Schizophrenia Bulletin</i> , 2003, 29, 803-830.	4.3	128
22	An overview of the genetics of psychotic mood disorders. <i>Journal of Psychiatric Research</i> , 2004, 38, 3-15.	3.1	84
23	Nonspecific and attenuated negative symptoms in patients at clinical high-risk for schizophrenia. <i>Schizophrenia Research</i> , 2004, 68, 37-48.	2.0	207
24	Functional magnetic resonance imaging during auditory verbal working memory in nonpsychotic relatives of persons with schizophrenia: a pilot study. <i>Biological Psychiatry</i> , 2004, 55, 490-500.	1.3	95
25	Temperament types are associated with weak self-construct, elevated distress and emotion-oriented coping in schizophrenia: evidence for a complex vulnerability marker?. <i>Psychiatry Research</i> , 2004, 128, 219-228.	3.3	42
26	Considering schizophrenia from a prevention perspective. <i>American Journal of Preventive Medicine</i> , 2004, 26, 178-185.	3.0	28
27	Early symptoms of mania and the role of parental risk. <i>Bipolar Disorders</i> , 2005, 7, 623-634.	1.9	89
28	Pathways to schizophrenic psychosis: A LISREL-tested model of the unfolding of the schizophrenic prodrome. <i>Journal of Clinical Psychology</i> , 2005, 61, 909-938.	1.9	12
29	Neuropsychological Functioning in Adolescents and Young Adults at Genetic Risk for Schizophrenia and Affective Psychoses: Results from the Harvard and Hillside Adolescent High Risk Studies. <i>Schizophrenia Bulletin</i> , 2005, 32, 507-524.	4.3	124
30	Searching for the Liability to Schizophrenia: Concepts and Methods Underlying Genetic High-Risk Studies of Adolescents. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2005, 15, 403-417.	1.3	37
31	Development from Birth to Adolescence of Children At-Risk for Schizophrenia. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2005, 15, 384-394.	1.3	21
32	Taxonic structure of schizotypal personality disorder: A multiple-instrument, multi-sample study based on mixture models. <i>Psychiatry Research</i> , 2005, 137, 71-85.	3.3	20
33	Cluster A Personality Disorders: A Review. , 2005, , 1-124.		39
34	Genetics and Family Influences on Olfaction: A Focus in Schizophrenia. , 0, , 167-182.		0
35	Taxonic structure of schizotypal personality in nonclinical subjects: Issues of replicability and age consistency. <i>Psychiatry Research</i> , 2007, 152, 103-112.	3.3	23
36	Plasma homovanillic acid levels in schizophrenic patients: Correlation with negative symptoms. <i>Psychiatry Research</i> , 2007, 151, 163-168.	3.3	12

#	ARTICLE	IF	CITATIONS
37	Competing Definitions of Schizophrenia: What Can Be Learned From Polydiagnostic Studies?. Schizophrenia Bulletin, 2007, 33, 1178-1200.	4.3	66
38	Long-term administration of the low-dose risperidone in schizotaxia subjects. Human Psychopharmacology, 2007, 22, 407-412.	1.5	8
39	Social Functioning Deficits in Young People at Risk for Schizophrenia. Australian and New Zealand Journal of Psychiatry, 2008, 42, 678-685.	2.3	47
40	Toward a better identification and treatment of schizophrenia prodrome. Bulletin of the Menninger Clinic, 2008, 72, 210-227.	0.6	8
41	Emotion Processing in Persons at Risk for Schizophrenia. Schizophrenia Bulletin, 2008, 34, 888-903.	4.3	151
42	The Schizotypal Ambivalence Scale as a Marker of Schizotypy. Journal of Nervous and Mental Disease, 2008, 196, 399-404.	1.0	13
43	Imaging Genetic Liability to Schizophrenia: Systematic Review of fMRI Studies of Patients' Nonpsychotic Relatives. Schizophrenia Bulletin, 2009, 35, 1142-1162.	4.3	123
44	The schizotaxic self: Phenotyping the silent predisposition to schizophrenia spectrum disorders. Medical Hypotheses, 2009, 73, 121-122.	1.5	8
45	Methodological issues in evaluating environmental risk factors on "apples and pears": A response to Logan. Medical Hypotheses, 2009, 73, 120-121.	1.5	0
46	Genetic Risks in Schizophrenia: Cross-National Prospective Longitudinal High-Risk Studies. , 2009, , 487-500.		2
47	Sustained Attention Deficit Along the Psychosis Proneness Continuum. Cognitive and Behavioral Neurology, 2009, 22, 180-185.	0.9	21
48	Do Low-Effort Learning Strategies Mediate Impaired Memory in ADHD?. Journal of Learning Disabilities, 2010, 43, 430-440.	2.2	40
49	Children of Parents With Affective and Nonaffective Psychoses: A Longitudinal Study of Behavior Problems. American Journal of Psychiatry, 2010, 167, 1331-1338.	7.2	30
50	Reduced intra-amygdala activity to positively valenced faces in adolescent schizophrenia offspring. Schizophrenia Research, 2010, 123, 126-136.	2.0	44
51	Ser9Gly polymorphism of the DRD3 gene is associated with worse premorbid social functioning and an earlier age of onset in female but not male schizophrenic patients. Psychiatry Research, 2010, 177, 266-267.	3.3	8
52	The Social Cognition and Interaction Training (SCIT): An extension to individuals with schizotypal personality features. Psychiatry Research, 2010, 178, 208-210.	3.3	19
53	Prevention of schizophrenia. Expert Review of Neurotherapeutics, 2010, 10, 1165-1174.	2.8	10
54	Early and broadly defined psychosis risk mental states. Schizophrenia Research, 2011, 126, 1-10.	2.0	105

#	ARTICLE	IF	CITATIONS
55	Neurocognitive predictors of functional outcome two to 13years after identification as ultra-high risk for psychosis. Schizophrenia Research, 2011, 132, 1-7.	2.0	182
56	Outcome of Severe Obsessive-compulsive Disorder With Schizotypal Features: A Pilot Study. Journal of the Formosan Medical Association, 2011, 110, 85-92.	1.7	15
57	Recent developments in neuropsychological endophenotypes for schizophrenia: Development of the MATRICS battery, liability syndromes and the near future. Science Bulletin, 2011, 56, 3385-3393.	1.7	1
58	The Silent Side of the Spectrum: Schizotypy and the Schizotaxic Self. Schizophrenia Bulletin, 2011, 37, 1017-1026.	4.3	130
59	Cognitive and Prepulse Inhibition Deficits in Psychometrically High Schizotypal Subjects in the General Population: Relevance to Schizophrenia Research. Journal of the International Neuropsychological Society, 2012, 18, 643-656.	1.8	54
60	The nature of schizotypy among multigenerational multiplex schizophrenia families.. Journal of Abnormal Psychology, 2012, 121, 396-406.	1.9	15
61	Auditory working memory impairments in individuals at familial high risk for schizophrenia.. Neuropsychology, 2012, 26, 288-303.	1.3	32
62	Neurocognitive profile and its association with psychopathology in first-degree relatives of patients with schizophrenia. A case-control study. Psychiatry Research, 2012, 200, 137-143.	3.3	15
63	Cognitive Impairment and Formal Thought Disorders in Parents of Early-Onset Schizophrenia Patients. Neuropsychobiology, 2012, 65, 206-215.	1.9	9
64	Neurocognitive and clinical dysfunction in adult Chinese, nonpsychotic relatives of patients with schizophrenia: Findings from the Changsha study and evidence for schizotaxia. Asian Journal of Psychiatry, 2012, 5, 83-92.	2.0	7
65	Are neurocognitive, clinical and social dysfunctions in schizotaxia reversible pharmacologically? Results from the Changsha study. Asian Journal of Psychiatry, 2012, 5, 73-82.	2.0	10
66	Neurocognition in youth and young adults under age 30 at familial risk for schizophrenia: A quantitative and qualitative review. Cognitive Neuropsychiatry, 2013, 18, 44-82.	1.3	142
67	The Relationship Between Personality Disorders and Axis I Psychopathology: Deconstructing Comorbidity. Annual Review of Clinical Psychology, 2013, 9, 529-554.	12.3	32
68	Prevention and Recovery in Early Psychosis (PREPÂ®): Building a public-academic partnership program in Massachusetts, United States. Asian Journal of Psychiatry, 2013, 6, 171-177.	2.0	23
69	Schizotypal Personality Disorder. Journal of Personality Disorders, 2013, 27, 652-679.	1.4	47
70	A review of neuroimaging studies of young relatives of individuals with schizophrenia: A developmental perspective from schizotaxia to schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 604-635.	1.7	95
71	Festschrift celebrating the career of Ming T. Tsuang. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 551-558.	1.7	1
72	Development of liability syndromes for schizophrenia: Where did they come from and where are they going?. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2013, 162, 687-697.	1.7	3

#	ARTICLE	IF	CITATIONS
73	Autism and Schizophrenia in Adults: Clinical Considerations on Comorbidity and Differential Diagnosis. , 2014, , 263-281.		11
74	Self-disorders and the Schizophrenia Spectrum: A Study of 100 First Hospital Admissions. Schizophrenia Bulletin, 2014, 40, 1300-1307.	4.3	161
75	Genetic and environmental bases of the interplay between magical ideation and personality. Psychiatry Research, 2014, 215, 453-459.	3.3	14
76	Neurocognitive performance in family-based and case-control studies of schizophrenia. Schizophrenia Research, 2015, 163, 17-23.	2.0	37
77	The concept of schizotypy â€” A computational anatomy perspective. Schizophrenia Research: Cognition, 2015, 2, 89-92.	1.3	13
79	Psychotogenesis. , 2021, , 13-31.		0
81	The Genetic Basis of Schizophrenia. , 2004, , 3-21.		7
82	Prevention of Schizophrenia and Psychotic Behavior. , 2004, , 255-283.		3
83	Neuroimaging Studies of Nonpsychotic First-Degree Relatives of People With Schizophrenia. , 2004, , 179-210.		3
84	High-risk studies and neurodevelopmental hypothesis. , 2002, , 71-82.		3
85	Does schizophrenia result from developmental or degenerative processes?. , 2002, , 129-147.		13
86	Neurological and Neuropsychological Endophenotypes in Schizophrenia Spectrum Disorders. , 2011, , 325-349.		2
87	Diagnosis and Classification of the Schizophrenia Spectrum Disorders. , 2011, , 45-83.		3
88	Education thÃ©rapeutique des patients psychotiques : impact sur la rÃ©-hospitalisation. Education Therapeutique Du Patient, 2010, 2, S125-S131.	1.0	10
89	Dysfunction of Cognition Patterns Measured by MATRICS Consensus Cognitive Battery (MCCB) among First Episode Schizophrenia Patients and Their Biological Parents. Shanghai Archives of Psychiatry, 2017, 29, 154-160.	0.7	7
90	A Study of Trait Anhedonia in Non-Clinical Chinese Samples: Evidence from the Chapman Scales for Physical and Social Anhedonia. PLoS ONE, 2012, 7, e34275.	2.5	85
91	Conceptualization of the liability for schizophrenia: clinical implications. Dialogues in Clinical Neuroscience, 1999, 1, 153-164.	3.7	2
92	A plausible model of schizophrenia must incorporate psychological and social, as well as neuro developmental, risk factors. Dialogues in Clinical Neuroscience, 2001, 3, 243-256.	3.7	11

#	ARTICLE	IF	CITATIONS
93	Premorbid Negative Symptoms in First-Episode Psychosis. European Journal of Psychiatry, 2007, 21, .	1.3	2
94	Schizophrenia: vulnerability versus disease. Dialogues in Clinical Neuroscience, 2000, 2, 257-266.	3.7	2
95	Schizophrenia: family studies and treatment of spectrum disorders. Dialogues in Clinical Neuroscience, 2000, 2, 381-391.	3.7	3
97	The Nature of Schizotaxia. , 2004, , 93-114.		0
98	Health-Related Quality of Life Impairment in Schizophrenia and Related Disorders as a Target for Neuroprotective Therapy. American Journal of Neuroprotection and Neuroregeneration, 2010, 2, 48-57.	0.1	1
101	Schizoaffective and schizotypal disorders. , 2012, , 595-602.		0
102	Functional and Dysfunctional Religious/Spiritual Beliefs in Psychotic Disorders. New Approaches To the Scientific Study of Religion, 2017, , 167-180.	0.3	1
103	Gene-environment interactions in mental disorders. World Psychiatry, 2004, 3, 73-83.	10.4	93
104	Changes in the DSM Diagnostic Concept of Schizophrenia: From 1980 to 2013. Journal of Korean Neuropsychiatric Association, 2021, 60, 241.	0.5	0